Joseph Therriault

Mar 13, 2024 | nature.com | Wagner S. Brum |Joseph Therriault |Eduardo Zimmer |Sebastian Palmqvist |Henrik Zetterberg |Kaj Blennow | +1 more

AbstractBlood-based biomarkers for screening may guide tau positrion emissition tomography (PET) scan referrals to optimize prognostic evaluation in Alzheimer’s disease. Plasma Aβ42/Aβ40, pTau181, pTau217, pTau231, NfL, and GFAP were measured along with tau-PET in memory clinic patients with subjective cognitive decline, mild cognitive impairment or dementia, in the Swedish BioFINDER-2 study (n = 548) and in the TRIAD study (n = 179).

Mar 11, 2024 | thelancet.com | Joseph Therriault |Nicholas Ashton |Ilaria Pola

SummaryBlood-based biomarkers of Alzheimer’s disease (AD) have become increasingly important as scalable tools for diagnosis and determining clinical trial eligibility. P-tau217 is the most promising due to its excellent sensitivity and specificity for AD-related pathological changes. We compared the performance of two commercially available plasma p-tau217 assays (ALZpath p-tau217 and Janssen p-tau217+) in 294 individuals cross-sectionally.

Mar 1, 2024 | nature.com | Joseph Therriault |Suzanne Schindler |Gemma Salvadó |Thomas K. Karikari |Melissa Murray |Inge M.W. Verberk | +5 more

AbstractDisease staging, whereby the spatial extent and load of brain pathology are used to estimate the severity of Alzheimer disease (AD), is pivotal to the gold-standard neuropathological diagnosis of AD. Current in vivo diagnostic frameworks for AD are based on abnormal concentrations of amyloid-β and tau in the cerebrospinal fluid or on PET scans, and breakthroughs in molecular imaging have opened up the possibility of in vivo staging of AD.

Sep 25, 2023 | nature.com | Bruna Bellaver |Guilherme Povala |Joseph Therriault |Cecile Tissot |Carolina Soares |Yi-ting Wang | +6 more

AbstractThe mechanisms by which the apolipoprotein E ε4 (APOEε4) allele influences the pathophysiological progression of Alzheimer’s disease (AD) are poorly understood. Here we tested the association of APOEε4 carriership and amyloid-β (Aβ) burden with longitudinal tau pathology.

Aug 31, 2023 | nature.com | Wagner S. Brum |Eduardo Zimmer |Joseph Therriault |Cecile Tissot |Hartmuth C. Kolb |Sebastian Palmqvist | +2 more

AbstractCost-effective strategies for identifying amyloid-β (Aβ) positivity in patients with cognitive impairment are urgently needed with recent approvals of anti-Aβ immunotherapies for Alzheimer’s disease (AD). Blood biomarkers can accurately detect AD pathology, but it is unclear whether their incorporation into a full diagnostic workflow can reduce the number of confirmatory cerebrospinal fluid (CSF) or positron emission tomography (PET) tests needed while accurately classifying patients.